A Phase-I Study Of Cyclical Oral Administration Of Temozolomide In Combination With PEG12000-Interferon Alfa-2B In Patients With Refractory And/Or Advanced Solid Tumors
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Peginterferon alfa-2b; Temozolomide
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 30 Mar 2018 Biomarkers information updated
- 20 Sep 2005 New trial record.